The Antiviral Mechanism of Pan-Serotype DENV Inhibitor JNJ-A07

JNJ-A07, a pan-serotype dengue virus (DENV) inhibitor, has demonstrated therapeutic activity against DENV infection in murine models. Though it is known to block the interaction between NS2B-NS3 and NS4B-containing proteins, its exact mechanism of action had not been discerned. Now, Kiemel et al. report that JNJ-A07 targets the interaction between NS2B-NS3 and the NS4A-2K-NS4B precursor, thereby preventing de novo formation of vesicle packet structures that are indispensable for viral RNA replication. In addition to providing a better understanding of JNJ-A07 activity, this work may also offer insight into the mechanisms-of-action of other NS4B-directed agents.

This study used four well-cited GeneTex antibodies, including Dengue virus NS3 protein antibody [GT2811] (GTX629477), Dengue virus NS4B protein antibody (GTX124250), Dengue virus NS2B protein antibody (GTX124246), and Zika virus NS4B protein antibody (GTX133321). GeneTex is now introducing its recombinant rabbit monoclonal Dengue virus NS3 protein antibody [HL2239] (GTX638284), Dengue virus NS2B protein antibody [HL2513] (GTX638874), and Zika virus NS4B protein antibody [HL1663] (GTX637261). GeneTex offers an unparalleled catalog of quality antibodies and reagents for flaviviruses and other viral pathogens. For more information, please visit the GENETEX WEBSITE.